A Study to Evaluate Safety and Efficacy of Elagolix Alone or Elagolix With Hormonal Add-Back in Subjects With Endometriosis With Associated Moderate to Severe Pain
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Elagolix (Primary) ; Ethinylestradiol/norethisterone (Primary)
- Indications Endometriosis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 04 Oct 2018 Status changed from recruiting to discontinued.
- 26 Jan 2018 Planned End Date changed from 18 Oct 2021 to 17 Nov 2021.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.